Home / Blog / Product Liability / Mylan N.V. expands injectable recall over risk of contamination

Mylan N.V. expands injectable recall over risk of contamination

Posted on June 8, 2015 9:12 am under Product Liability

Mylan N.V. has expanded its recall of certain Gemcitabine and Methotrexate injectables to hospital/user level due to the presence of foreign particulate matters that may pose adverse health complications, the U.S. Food and Drug Administration reported on June 8.

The FDA released a detailed list of Gemcitabine and Methotrexate injectables covered by the recall. Affected Gemcitabine Injections were distributed in the country from January 8, 2014 to February 10, 2015 for treatment of certain types of cancer. Methotrexate Injections, on the other hand, were distributed between December 8, 2014 and December 19, 2014 for treatment of certain neoplastic illnesses, such as rheumatoid arthritis and severe psoriasis.

When administered, injections contaminated with foreign matter increase your risk of serious medical complications, such as thrombosis, phlebitis, inflammation of the affected area, and allergic reaction. To learn more about taking legal action after being harmed by a defective medical product in Milwaukee, speak with our team of product liability attorneys at Habush Habush & Rottier S.C. ®, who might be able to help you file a claim against the manufacturer involved. Call us at (414) 271-0900 and tell us more about your situation today.